HPA-23

Identification

Generic Name

HPA-23

DrugBank Accession Number

DB17739

Background

HPA-23 is an investigational antiviral compound.¹

Type

Small Molecule

Groups

Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for HPA-23 (DB17739)

×

Close

Weight

Average: 6685.04
Monoisotopic: 6679.2293

Chemical Formula

H₆₈N₁₇Na₂O₈₆Sb₉W₂₁

Synonyms

• Ammonium 21-tungsto-9-antimoniate
• Ammonium antimony sodium tungsten oxide ((nh4)17sb9na2w21o86)
• Tungstate(19-), hexaoctacontaoxononaantimonateheneicosa-, heptadecaammonium disodium

External IDs

• HPA 23
• HPA-23
• HPA23
• PM-71

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

Not Available

Categories

Drug Categories

• Anti-Infective Agents
• Antineoplastic Agents
• Antiviral Agents
• Elements
• Metalloids
• Metals
• Metals, Heavy

Classification

Not classified

Affected organisms

Not Available

Chemical Identifiers

UNII

J08H62IZC9

CAS number

89899-81-0

InChI Key

HIMFWDDKEANLEL-UHFFFAOYSA-A

InChI

InChI=1S/17H3N.2Na.86O.9Sb.21W/h17*1H3;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/q;;;;;;;;;;;;;;;;;2*+2;86*-2;9*+3;21*+6/p+17

IUPAC Name

henicosatungsten(6+) nonaantimony(3+) disodium(2+) heptadecaammonium hexaoctacontaoxidandiide

SMILES

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a++].[Na++].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6]

References

General References

1. Kimberlin RH, Walker CA: The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol. 1983;78(1-2):9-18. doi: 10.1007/BF01310854. [Article]

External Links

Wikipedia

HPA-23

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-0.98	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	0	Chemaxon
Hydrogen Donor Count	1	Chemaxon
Polar Surface Area	0 Å2	Chemaxon
Rotatable Bond Count	0	Chemaxon
Refractivity	16.31 m3·mol-1	Chemaxon
Polarizability	2.38 Å3	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Chromatographic Properties

Collision Cross Sections (CCS)

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at May 03, 2023 16:19 / Updated at July 18, 2023 22:59